SUPN

$30.4827.29%-11.44

Supernus Pharmaceuticals Inc (SUPN)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$41.92

Offen:

$28.35

24-Stunden-Volumen:

980,487

Relatives Volumen:

0.72

Marktkapitalisierung:

$1.78B

Einnahmen:

$776.83M

Nettoeinkommen (Verlust:

-$29.02M

KGV:

EPS:

-$0.512

Netto-Cashflow:

$82.25M

1W Leistung:

-25.59%

1M Leistung:

-28.08%

6M Leistung:

-36.30%

1Y Leistung:

-45.28%

1-Tages-Spanne:

$28.35$31.20

1-Wochen-Bereich:

$39.53$44.31

52-Wochen-Spanne:

$28.35$59.68

Supernus Pharmaceuticals Inc Aktie (SUPN) Unternehmensprofil

Firmenname

Supernus Pharmaceuticals Inc

Sektor

Healthcare

Branche

Drug Manufacturers - Specialty & Generic

Telefon

301-838-2500

Adresse

9715 KEY WEST AVENUE, ROCKVILLE, MD, USA

Mitarbeiter

778

@Supernus_Pharma

Nächster Verdiensttermin

null

Neueste SEC-Einreichungen

SEC

SUPN-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Supernus Pharmaceuticals Inc Aktie (SUPN) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2025-10-09	Hochstufung	Piper Sandler	Neutral → Overweight
2025-07-30	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-02-19	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-01-06	Eingeleitet	Cantor Fitzgerald	Overweight
2024-09-11	Herabstufung	Piper Sandler	Overweight → Neutral
2023-01-03	Resumed	Jefferies	Buy
2021-12-01	Resumed	Jefferies	Buy
2021-04-13	Hochstufung	Jefferies	Hold → Buy
2020-06-16	Hochstufung	Piper Sandler	Neutral → Overweight
2020-06-15	Resumed	Jefferies	Hold
2019-11-08	Herabstufung	Berenberg	Buy → Hold
2019-11-07	Herabstufung	Stifel	Buy → Hold
2019-11-06	Herabstufung	Jefferies	Buy → Hold
2018-11-12	Bestätigt	B. Riley FBR	Buy
2018-01-18	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-28	Bestätigt	B. Riley FBR, Inc.	Buy
2017-12-04	Hochstufung	Janney	Neutral → Buy
2017-11-08	Hochstufung	Stifel	Hold → Buy
2017-10-19	Eingeleitet	FBR & Co.	Buy
2017-09-19	Herabstufung	Stifel	Buy → Hold
2017-07-17	Herabstufung	Piper Jaffray	Overweight → Neutral
2017-07-14	Eingeleitet	Janney	Neutral
2017-06-01	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-07-18	Herabstufung	Northland Capital	Outperform → Market Perform
2016-07-18	Herabstufung	Piper Jaffray	Overweight → Neutral
2016-02-08	Hochstufung	Jefferies	Hold → Buy
2015-11-05	Bestätigt	Northland Capital	Outperform
2015-10-28	Eingeleitet	Northland Capital	Outperform

Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)

Zeitraum	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2021-12-31	2020-12-31
Revenue USD (M)	718.95	661.82	667.24	579.78	520.40
Cost of revenue USD (M)	74.56	77.91	-	-	52.46
Gross profit USD (M)	-	-	-	-	467.94
Research and development USD (M)	106.24	108.80	74.55	90.47	75.96
Operating expenses USD (M)	781.24	580.15	621.11	493.75	294.24
Operating income USD (M)	-62.28	81.67	46.12	86.03	173.70
Income before tax USD (M)	-49.03	97.87	60.74	73.18	168.65
Income tax expense USD (M)	-10.48	24.01	0.03	19.75	41.70
Net income USD (M)	-38.55	73.87	60.71	53.42	126.95
Basic EPS USD/shares	-0.68	1.34	1.13	1.01	2.41
Diluted EPS USD/shares	-0.68	1.32	1.04	0.98	2.36
Basic weighted shares shares (M)	56.45	55.10	53.67	53.10	52.62
Diluted weighted shares shares (M)	56.45	55.96	61.68	54.36	53.69
Selling, general and administrative USD (M)	485.56	321.58	377.22	304.76	200.68

Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel

Rubin JonathanAug 12 '26
SVP, Chief Medical Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
750
Wert ($)
0
#Aktien Gesamt
14,342
DEC TIMOTHY CAug 12 '26
Senior Vice-President & CFO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,250
Wert ($)
0
#Aktien Gesamt
9,733
Khattar Jack A.Aug 12 '26
President, CEO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
29,849
Wert ($)
0
#Aktien Gesamt
1,270,993
Mottola FrankAug 12 '26
SVP, Chief Tech. Ops. Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,650
Wert ($)
0
#Aktien Gesamt
20,341
Bhatt Padmanabh P.Aug 12 '26
Sr. VP of IP, CSO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
2,500
Wert ($)
0
#Aktien Gesamt
19,795
Bhatt Padmanabh P.Mar 18 '26
Sr. VP of IP, CSO
Transaktion
Option Exercise
Kosten
$39.40
#Aktien
7,250
Wert ($)
285,650
#Aktien Gesamt
24,294
Bhatt Padmanabh P.Mar 18 '26
Sr. VP of IP, CSO
Transaktion
Sale
Kosten
$49.60
#Aktien
7,250
Wert ($)
359,621
#Aktien Gesamt
17,044
Bhatt Padmanabh P.Mar 17 '26
Sr. VP of IP, CSO
Transaktion
Option Exercise
Kosten
$38.51
#Aktien
50,000
Wert ($)
1,925,537
#Aktien Gesamt
67,044
PADMANABH P BHATTMar 17 '26
Officer
Transaktion
Proposed Sale
Kosten
$50.21
#Aktien
57,250
Wert ($)
2,874,522
#Aktien Gesamt
0
Bhatt Padmanabh P.Mar 17 '26
Sr. VP of IP, CSO
Transaktion
Sale
Kosten
$50.30
#Aktien
50,000
Wert ($)
2,514,886
#Aktien Gesamt
17,044

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Rubin Jonathan	SVP, Chief Medical Officer	Aug 12 '26	Option Exercise	$0.00	750	0	14,342
DEC TIMOTHY C	Senior Vice-President & CFO	Aug 12 '26	Option Exercise	$0.00	1,250	0	9,733
Khattar Jack A.	President, CEO	Aug 12 '26	Option Exercise	$0.00	29,849	0	1,270,993
Mottola Frank	SVP, Chief Tech. Ops. Officer	Aug 12 '26	Option Exercise	$0.00	1,650	0	20,341
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Aug 12 '26	Option Exercise	$0.00	2,500	0	19,795
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Option Exercise	$39.40	7,250	285,650	24,294
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 18 '26	Sale	$49.60	7,250	359,621	17,044
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Option Exercise	$38.51	50,000	1,925,537	67,044
PADMANABH P BHATT	Officer	Mar 17 '26	Proposed Sale	$50.21	57,250	2,874,522	0
Bhatt Padmanabh P.	Sr. VP of IP, CSO	Mar 17 '26	Sale	$50.30	50,000	2,514,886	17,044

Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten

Nov 02, 2026

Why Indivior Pharmaceuticals Stock Topped the Market Today - The Motley Fool

Nov 02, 2026

Oct 31, 2026

SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger - Yahoo Finance

Oct 31, 2026

Oct 30, 2026